 [1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes METOPROLOL TARTRATE increase or decrease the risk [0m
[34mof myocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes METOPROLOL TARTRATE increase or decrease the risk [0m
[32mof myocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes METOPROLOL TARTRATE increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"METOPROLOL TARTRATE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: METOPROLOL TARTRATE: pharmacokinetics: Renal Impairment The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree [0m
[31mfrom those in normal subjects. Hepatic Impairment Since the drug is primarily eliminated by hepatic metabolism, hepatic impairment may impact the pharmacokinetics of metoprolol. The elimination [0m
[31mhalf-life of metoprolol is considerably prolonged, depending on severity [0m[1;31m([0m[31mup to [0m[1;31m7.2[0m[31m h[0m[1;31m)[0m[31m. Clinical Studies Hypertension In controlled clinical studies, metoprolol has been shown to be an effective [0m
[31mantihypertensive agent when used alone or as concomitant therapy with thiazide-type diuretics, at dosages of [0m[1;31m100[0m[31m to [0m[1;31m450[0m[31m mg daily. METOPROLOL TARTRATE: pharmacokinetics: In controlled, comparative, [0m
[31mclinical studies, metoprolol has been shown to be as effective an antihypertensive agent as propranolol, methyldopa, and thiazide-type diuretics, to be equally effective in supine and standing [0m
[31mpositions. Angina Pectoris In controlled clinical trials, metoprolol, administered two or four times daily, has been shown to be an effective antianginal agent, reducing the number of angina attacks [0m
[31mand increasing exercise tolerance. The dosage used in these studies ranged from [0m[1;31m100[0m[31m to [0m[1;31m400[0m[31m mg daily. A controlled, comparative, clinical trial showed that metoprolol was indistinguishable from [0m
[31mpropranolol in the treatment of angina pectoris. METOPROLOL TARTRATE: pharmacokinetics: Myocardial Infarction In a large [0m[1;31m([0m[1;31m1[0m[31m,[0m[1;31m395[0m[31m patients randomized[0m[1;31m)[0m[31m, double-blind, placebo-controlled clinical study, [0m
[31mmetoprolol was shown to reduce [0m[1;31m3[0m[31m-month mortality by [0m[1;31m36[0m[31m% in patients with suspected or definite myocardial infarction. Patients were randomized and treated as soon as possible after their arrival in [0m
[31mthe hospital, once their clinical condition had stabilized and their hemodynamic status had been carefully evaluated. Subjects were ineligible if they had hypotension, bradycardia, peripheral signs of[0m
[31mshock, and/or more than minimal basal rales as signs of congestive heart failure. Initial treatment consisted of intravenous followed by oral administration of metoprolol or placebo, given in a [0m
[31mcoronary care or comparable unit. Oral maintenance therapy with metoprolol or placebo was then continued for [0m[1;31m3[0m[31m months. After this double-blind period, all patients were given metoprolol and followed [0m
[31mup to [0m[1;31m1[0m[31m year. METOPROLOL TARTRATE: pharmacokinetics: The median delay from the onset of symptoms to the initiation of therapy was [0m[1;31m8[0m[31m hours in both the metoprolol- and placebo-treatment groups. Among [0m
[31mpatients treated with metoprolol, there were comparable reductions in [0m[1;31m3[0m[31m-month mortality for those treated early [0m[1;31m([0m[31mâ‰¤[0m[1;31m8[0m[31m hours[0m[1;31m)[0m[31m and those in whom treatment was started later. Significant reductions in the [0m
[31mincidence of ventricular fibrillation and in chest pain following initial intravenous therapy were also observed with metoprolol and were independent of the interval between onset of symptoms and [0m
[31minitiation of therapy. In this study, patients treated with metoprolol received the drug both very early [0m[1;31m([0m[31mintra-venously[0m[1;31m)[0m[31m and during a subsequent [0m[1;31m3[0m[31m-month period, while placebo patients received no [0m
[31mbeta-blocker treatment for this period. The study thus was able to show a benefit from the overall metoprolol regimen but cannot separate the benefit of very early intravenous treatment from the [0m
[31mbenefit of later beta-blocker therapy. METOPROLOL TARTRATE: pharmacokinetics: Nonetheless, because the overall regimen showed a clear beneficial effect on survival without evidence of an early adverse[0m
[31meffect on survival, one acceptable dosage regimen is the precise regimen used in the trial. Because the specific benefit of very early treatment remains to be defined however, it is also reasonable to[0m
[31madminister the drug orally to patients at a later time as is recommended for certain other beta-blockers.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: carcinogenesis_and_mutagenesis_and_impairment_of_fertility: Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have been conducted to [0m
[31mevaluate carcinogenic potential. In a [0m[1;31m2[0m[31m-year study in rats at three oral dosage levels of up to [0m[1;31m800[0m[31m mg/kg per day, there was no increase in the development of spontaneously occurring benign or [0m
[31mmalignant neoplasms of any type. The only histologic changes that appeared to be drug related were an increased incidence of generally mild focal accumulation of foamy macrophages in pulmonary alveoli[0m
[31mand a slight increase in biliary hyperplasia. In a [0m[1;31m21[0m[31m-month study in Swiss albino mice at three oral dosage levels of up to [0m[1;31m750[0m[31m mg/kg per day, benign lung tumors [0m[1;31m([0m[31msmall adenomas[0m[1;31m)[0m[31m occurred more [0m
[31mfrequently in female mice receiving the highest dose than in untreated control animals. There was no increase in malignant or total [0m[1;31m([0m[31mbenign plus malignant[0m[1;31m)[0m[31m lung tumors, or in the overall incidence of [0m
[31mtumors or malignant tumors. METOPROLOL TARTRATE: carcinogenesis_and_mutagenesis_and_impairment_of_fertility: This [0m[1;31m21[0m[31m-month study was repeated in CD-[0m[1;31m1[0m[31m mice, and no statistically or biologically [0m
[31msignificant differences were observed between treated and control mice of either sex for any type of tumor. All mutagenicity tests performed [0m[1;31m([0m[31ma dominant lethal study in mice, chromosome studies in [0m
[31msomatic cells, a Salmonella/mammalian-microsome mutagenicity test, and a nucleus anomaly test in somatic interphase nuclei[0m[1;31m)[0m[31m were negative. Reproduction toxicity studies in mice, rats and rabbits did [0m
[31mnot indicate teratogenic potential for metoprolol tartrate. Embryotoxicity and/or fetotoxicity in rats and rabbits were noted starting at doses of [0m[1;31m50[0m[31m mg/kg in rats and [0m[1;31m25[0m[31m mg/kg in rabbits, as [0m
[31mdemonstrated by increases in preimplantation loss, decreases in the number of viable fetuses per dose, and/or decreases in neonatal survival. METOPROLOL TARTRATE: [0m
[31mcarcinogenesis_and_mutagenesis_and_impairment_of_fertility: High doses were associated with some maternal toxicity, and growth delay of the offspring in utero , which was reflected in minimally lower [0m
[31mweights at birth. The oral NOAELs for embryo-fetal development in mice, rats, and rabbits were considered to be [0m[1;31m25[0m[31m, [0m[1;31m200[0m[31m, and [0m[1;31m12.5[0m[31m mg/kg. This corresponds to dose levels that are approximately [0m[1;31m0.3[0m[31m, [0m[1;31m4[0m[31m, [0m
[31mand [0m[1;31m0.5[0m[31m times, respectively, when based on surface area, the maximum human oral dose [0m[1;31m([0m[1;31m8[0m[31m mg/kg/day[0m[1;31m)[0m[31m of metoprolol tartrate. Metoprolol tartrate has been associated with reversible adverse effects on [0m
[31mspermatogenesis starting at oral dose levels of [0m[1;31m3.5[0m[31m mg/kg in rats [0m[1;31m([0m[31ma dose that is only [0m[1;31m0.1[0m[31m-times the human dose, when based on surface area[0m[1;31m)[0m[31m, although other studies have shown no effect of metoprolol [0m
[31mtartrate on reproductive performance in male rats.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: dosage_and_administration: DOSAGE AND ADMINISTRATION Hypertension Individualized the dosage of metoprolol tartrate tablets. Metoprolol tartrate tablets should be taken [0m
[31mwith or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily in single or divided doses, whether used alone or added to a diuretic. Increase the dosage [0m
[31mat weekly [0m[1;31m([0m[31mor longer[0m[1;31m)[0m[31m intervals until optimum blood pressure reduction is achieved. In general, the maximum effect of any given dosage level will be apparent after [0m[1;31m1[0m[31m week of therapy. The effective [0m
[31mdosage range of metoprolol tartrate tablets is [0m[1;31m100[0m[31m to [0m[1;31m450[0m[31m mg per day. Dosages above [0m[1;31m450[0m[31m mg per day have not been studied. METOPROLOL TARTRATE: dosage_and_administration: While once-daily dosing is [0m
[31meffective and can maintain a reduction in blood pressure throughout the day, lower doses [0m[1;31m([0m[31mespecially [0m[1;31m100[0m[31m mg[0m[1;31m)[0m[31m may not maintain a full effect at the end of the [0m[1;31m24[0m[31m-hour period, and larger or more [0m
[31mfrequent daily doses may be required. This can be evaluated by measuring blood pressure near the end of the dosing interval to determine whether satisfactory control is being maintained throughout the[0m
[31mday. Beta [0m[1;31m1[0m[31m selectivity diminishes as the dose of metoprolol is increased. Angina Pectoris The dosage of metoprolol tartrate tablets should be individualized. Metoprolol tartrate tablets should be [0m
[31mtaken with or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily, given in two divided doses. Gradually increase the dosage at weekly intervals until [0m
[31moptimum clinical response has been obtained or there is pronounced slowing of the heart rate. METOPROLOL TARTRATE: dosage_and_administration: The effective dosage range of metoprolol tartrate tablets [0m
[31mis [0m[1;31m100[0m[31m to [0m[1;31m400[0m[31m mg per day. Dosages above [0m[1;31m400[0m[31m mg per day have not been studied. If treatment is to be discontinued, gradually decrease the dosage over a period of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m weeks [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. [0m
[31mMyocardial Infarction Early Treatment During the early phase of definite or suspected acute myocardial infarction, initiate treatment with metoprolol tartrate tablets as soon as possible after the [0m
[31mpatient's arrival in the hospital. Such treatment should be initiated in a coronary care or similar unit immediately after the patientâ€™s hemodynamic condition has stabilized. Begin treatment in this [0m
[31mearly phase with the intravenous administration of three bolus injections of [0m[1;31m5[0m[31m mg of metoprolol tartrate each; give the injections at approximately [0m[1;31m2[0m[31m-minute intervals. During the intravenous [0m
[31madministration of metoprolol, monitor blood pressure, heart rate, and electrocardiogram. METOPROLOL TARTRATE: dosage_and_administration: In patients who tolerate the full intravenous dose [0m[1;31m([0m[1;31m15[0m[31m mg[0m[1;31m)[0m[31m, [0m
[31minitiate metoprolol tartrate tablets, [0m[1;31m50[0m[31m mg every [0m[1;31m6[0m[31m hours, [0m[1;31m15[0m[31m minutes after the last intravenous dose and continue for [0m[1;31m48[0m[31m hours. Thereafter, the maintenance dosage is [0m[1;31m100[0m[31m mg twice daily [0m[1;31m([0m[31msee Late [0m
[31mTreatment below[0m[1;31m)[0m[31m. Start patients who appear not to tolerate the full intravenous dose on metoprolol tartrate tablets either [0m[1;31m25[0m[31m mg or [0m[1;31m50[0m[31m mg every [0m[1;31m6[0m[31m hours [0m[1;31m([0m[31mdepending on the degree of intolerance[0m[1;31m)[0m[31m [0m[1;31m15[0m[31m [0m
[31mminutes after the last intravenous dose or as soon as their clinical condition allows. In patients with severe intolerance, discontinue metoprolol tartrate tablets [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. METOPROLOL [0m
[31mTARTRATE: dosage_and_administration: Late Treatment Start patients with contraindications to treatment during the early phase of suspected or definite myocardial infarction, patients who appear not to[0m
[31mtolerate the full early treatment, and patients in whom the physician wishes to delay therapy for any other reason on metoprolol tartrate tablets, [0m[1;31m100[0m[31m mg twice daily, as soon as their clinical [0m
[31mcondition allows. Continue therapy for at least [0m[1;31m3[0m[31m months. Although the efficacy of metoprolol beyond [0m[1;31m3[0m[31m months has not been conclusively established, data from studies with other beta-blockers suggest [0m
[31mthat treatment should be continued for [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m years. Special Populations Pediatric Patients : No pediatric studies have been performed. The safety and efficacy of metoprolol tartrate tablets in [0m
[31mpediatric patients have not been established. Renal Impairment : No dose adjustment of metoprolol tartrate tablets is required in patients with renal impairment.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: clinical_pharmacology: CLINICAL PHARMACOLOGY Mechanism of Action Metoprolol tartrate is a beta [0m[1;31m1[0m[31m -selective [0m[1;31m([0m[31mcardioselective[0m[1;31m)[0m[31m adrenergic receptor blocker. This [0m
[31mpreferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta [0m[1;31m2[0m[31m -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Clinical[0m
[31mpharmacology studies have demonstrated the beta-blocking activity of metoprolol, as shown by [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in heart rate and cardiac output at rest and upon exercise, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic blood [0m
[31mpressure upon exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol-induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m reduction of reflex orthostatic tachycardia. Hypertension The mechanism of the antihypertensive effects of [0m
[31mbeta-blocking agents has not been fully elucidated. METOPROLOL TARTRATE: clinical_pharmacology: However, several possible mechanisms have been proposed: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at[0m
[31mperipheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output; [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central effect leading to reduced sympathetic outflow to the periphery; and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin[0m
[31mactivity. Angina Pectoris By blocking catecholamine-induced increases in heart rate, in velocity and extent of myocardial contraction, and in blood pressure, metoprolol reduces the oxygen requirements[0m
[31mof the heart at any given level of effort, thus making it useful in the long-term management of angina pectoris. Myocardial Infarction The precise mechanism of action of metoprolol in patients with [0m
[31msuspected or definite myocardial infarction is not known. METOPROLOL TARTRATE: clinical_pharmacology: Pharmacodynamics Relative beta [0m[1;31m1[0m[31m selectivity is demonstrated by the following: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m In healthy [0m
[31msubjects, metoprolol is unable to reverse the beta [0m[1;31m2[0m[31m -mediated vasodilating effects of epinephrine. This contrasts with the effect of nonselective [0m[1;31m([0m[31mbeta [0m[1;31m1[0m[31m plus beta [0m[1;31m2[0m[31m [0m[1;31m)[0m[31m beta-blockers, which completely[0m
[31mreverse the vasodilating effects of epinephrine. [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m In asthmatic patients, metoprolol reduces FEV [0m[1;31m1[0m[31m and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta [0m[1;31m1[0m[31m [0m
[31m-receptor blocking doses. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at doses much greater than required for beta-blockade. Animal and [0m
[31mhuman experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction. METOPROLOL TARTRATE: clinical_pharmacology: Significant beta-blocking effect [0m[1;31m([0m[31mas measured by [0m
[31mreduction of exercise heart rate[0m[1;31m)[0m[31m occurs within [0m[1;31m1[0m[31m hour after oral administration, and its duration is dose-related. For example, a [0m[1;31m50[0m[31m% reduction of the maximum effect after single oral doses of [0m[1;31m20[0m[31m, [0m
[1;31m50[0m[31m, and [0m[1;31m100[0m[31m mg occurred at [0m[1;31m3.3[0m[31m, [0m[1;31m5[0m[31m, and [0m[1;31m6.4[0m[31m hours, respectively, in normal subjects. After repeated oral dosages of [0m[1;31m100[0m[31m mg twice daily, a significant reduction in exercise systolic blood pressure was [0m
[31mevident at [0m[1;31m12[0m[31m hours. When the drug was infused over a [0m[1;31m10[0m[31m-minute period, in normal volunteers, maximum beta-blockade was achieved at approximately [0m[1;31m20[0m[31m minutes. Equivalent maximal beta-blocking effect is[0m
[31machieved with oral and intravenous doses in the ratio of approximately [0m[1;31m2.5[0m[31m:[0m[1;31m1[0m[31m. There is a linear relationship between the log of plasma levels and reduction of exercise heart rate. However, [0m
[31mantihypertensive activity does not appear to be related to plasma levels.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: spl_id         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: package_ndc         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: product_ndc         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: spl_set_id         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: overdosage: OVERDOSAGE Acute Toxicity Several cases of overdosage have been reported, some leading to death. Oral LD [0m[1;31m50[0m[31m â€™s [0m[1;31m([0m[31mmg/kg[0m[1;31m)[0m[31m: mice, [0m[1;31m1158[0m[31m to [0m[1;31m2460[0m[31m; rats, [0m[1;31m3090[0m[31m to [0m
[1;31m4670[0m[31m. Signs and Symptoms Potential signs and symptoms associated with overdosage with metoprolol are bradycardia, hypotension, bronchospasm, myocardial infarction, cardiac failure and death. [0m
[31mManagement There is no specific antidote. In general, patients with acute or recent myocardial infarction may be more hemodynamically unstable than other patients and should be treated accordingly [0m
[1;31m([0m[31msee WARNINGS, Myocardial Infarction [0m[1;31m)[0m[31m. On the basis of the pharmacologic actions of metoprolol, the following general measures should be employed: Elimination of the Drug: Gastric lavage should be [0m
[31mperformed. Other clinical manifestations of overdose should be managed symptomatically based on modern methods of intensive care. METOPROLOL TARTRATE: overdosage: Hypotension: Administer a [0m
[31mvasopressor, e.g., levarterenol or dopamine. Bronchospasm: Administer a beta [0m[1;31m2[0m[31m -stimulating agent and/or a theophylline derivative. Cardiac Failure: Administer digitalis glycoside and diuretic. In [0m
[31mshock resulting from inadequate cardiac contractility, consider administration of dobutamine, isoproterenol or glucagon.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: indications_and_usage: INDICATIONS AND USAGE Hypertension Metoprolol tartrate tablets, USP are indicated for the treatment of hypertension. They may be used alone or in [0m
[31mcombination with other antihypertensive agents. Angina Pectoris Metoprolol tartrate tablets, USP are indicated in the long-term treatment of angina pectoris. Myocardial Infarction Metoprolol tartrate [0m
[31mtablets, USP are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in [0m
[31mconjunction with intravenous metoprolol. Oral metoprolol tartrate tablets, USP therapy can be initiated after intravenous metoprolol therapy or, alternatively, oral treatment can begin within [0m[1;31m3[0m[31m to [0m[1;31m10[0m[31m [0m
[31mdays of the acute event [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: precautions: In a [0m[1;31m21[0m[31m-month study in Swiss albino mice at three oral dosage levels of up to [0m[1;31m750[0m[31m mg/kg per day, benign lung tumors [0m[1;31m([0m[31msmall adenomas[0m[1;31m)[0m[31m occurred more frequently[0m
[31min female mice receiving the highest dose than in untreated control animals. There was no increase in malignant or total [0m[1;31m([0m[31mbenign plus malignant[0m[1;31m)[0m[31m lung tumors, or in the overall incidence of tumors or [0m
[31mmalignant tumors. This [0m[1;31m21[0m[31m-month study was repeated in CD-[0m[1;31m1[0m[31m mice, and no statistically or biologically significant differences were observed between treated and control mice of either sex for any type [0m
[31mof tumor. All mutagenicity tests performed [0m[1;31m([0m[31ma dominant lethal study in mice, chromosome studies in somatic cells, a Salmonella/mammalian-microsome mutagenicity test, and a nucleus anomaly test in [0m
[31msomatic interphase nuclei[0m[1;31m)[0m[31m were negative. Reproduction toxicity studies in mice, rats and rabbits did not indicate teratogenic potential for metoprolol tartrate. METOPROLOL TARTRATE: precautions: [0m
[31mEmbryotoxicity and/or fetotoxicity in rats and rabbits were noted starting at doses of [0m[1;31m50[0m[31m mg/kg in rats and [0m[1;31m25[0m[31m mg/kg in rabbits, as demonstrated by increases in preimplantation loss, decreases in the [0m
[31mnumber of viable fetuses per dose, and/or decreases in neonatal survival. High doses were associated with some maternal toxicity, and growth delay of the offspring in utero , which was reflected in [0m
[31mminimally lower weights at birth. The oral NOAELs for embryo-fetal development in mice, rats, and rabbits were considered to be [0m[1;31m25[0m[31m, [0m[1;31m200[0m[31m, and [0m[1;31m12.5[0m[31m mg/kg. This corresponds to dose levels that are [0m
[31mapproximately [0m[1;31m0.3[0m[31m, [0m[1;31m4[0m[31m, and [0m[1;31m0.5[0m[31m times, respectively, when based on surface area, the maximum human oral dose [0m[1;31m([0m[1;31m8[0m[31m mg/kg/day[0m[1;31m)[0m[31m of metoprolol tartrate. METOPROLOL TARTRATE: precautions: Metoprolol tartrate [0m
[31mhas been associated with reversible adverse effects on spermatogenesis starting at oral dose levels of [0m[1;31m3.5[0m[31m mg/kg in rats [0m[1;31m([0m[31ma dose that is only [0m[1;31m0.1[0m[31m-times the human dose, when based on surface area[0m[1;31m)[0m[31m, [0m
[31malthough other studies have shown no effect of metoprolol tartrate on reproductive performance in male rats. Pregnancy Category C Upon confirming the diagnosis of pregnancy, women should immediately [0m
[31minform the doctor. Metoprolol has been shown to increase postimplantation loss and decrease neonatal survival in rats at doses up to [0m[1;31m11[0m[31m times the maximum daily human dose of [0m[1;31m450[0m[31m mg, when based on [0m
[31msurface area. Distribution studies in mice confirm exposure of the fetus when metoprolol is administered to the pregnant animal. These limited animal studies do not indicate direct or indirect harmful[0m
[31meffects with respect to teratogenicity [0m[1;31m([0m[31msee Carcinogenesis, Mutagenesis, Impairment of Fertility [0m[1;31m)[0m[31m. METOPROLOL TARTRATE: precautions: There are no adequate and well-controlled studies in pregnant [0m
[31mwomen. The amount of data on the use of metoprolol in pregnant women is limited. The risk to the fetus/mother is unknown. Because animal reproduction studies are not always predictive of human [0m
[31mresponse, this drug should be used during pregnancy only if clearly needed. Nursing Mothers Metoprolol is excreted in breast milk in a very small quantity. An infant consuming [0m[1;31m1[0m[31m liter of breast milk [0m
[31mdaily would receive a dose of less than [0m[1;31m1[0m[31m mg of the drug. Fertility The effects of metoprolol on the fertility of human have not been studied. Metoprolol showed effects on spermatogenesis in male rats[0m
[31mat a therapeutic dose level, but had no effect on rates of conception at higher doses in animal fertility studies [0m[1;31m([0m[31msee Carcinogenesis, Mutagenesis, Impairment of Fertility [0m[1;31m)[0m[31m. Pediatric Use Safety and [0m
[31meffectiveness in pediatric patients have not been established. METOPROLOL TARTRATE: geriatric_use: Geriatric Use Clinical trials of metoprolol in hypertension did not include sufficient numbers of [0m
[31melderly patients to determine whether patients over [0m[1;31m65[0m[31m years of age differ from younger subjects in their response to metoprolol. Other reported clinical experience in elderly hypertensive patients [0m
[31mhas not identified any difference in response from younger patients. In worldwide clinical trials of metoprolol in myocardial infarction, where approximately [0m[1;31m478[0m[31m patients were over [0m[1;31m65[0m[31m years of age [0m[1;31m([0m[1;31m0[0m[31m [0m
[31mover [0m[1;31m75[0m[31m years of age[0m[1;31m)[0m[31m, no age-related differences in safety and effectiveness were found. Other reported clinical experience in myocardial infarction has not identified differences in response between[0m
[31mthe elderly and younger patients. However, greater sensitivity of some elderly individuals taking metoprolol cannot be categorically ruled out. Therefore, in general, it is recommended that dosing [0m
[31mproceed with caution in this population.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: drug_interactions: Drug Interactions Catecholamine-depleting Drugs: Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given with [0m
[31mbeta-blocking agents or monoamine oxidase [0m[1;31m([0m[31mMAO[0m[1;31m)[0m[31m inhibitors. Observe patients treated with metoprolol plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce [0m
[31mvertigo, syncope, or postural hypotension. In addition, possibly significant hypertension may theoretically occur up to [0m[1;31m14[0m[31m days following discontinuation of the concomitant administration with an [0m
[31mirreversible MAO inhibitor. Digitalis Glycosides and Beta-blockers: Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase [0m
[31mthe risk of bradycardia. Monitor heart rate and PR interval. METOPROLOL TARTRATE: drug_interactions: Calcium Channel Blockers: Concomitant administration of a beta-adrenergic antagonist with a calcium[0m
[31mchannel blocker may produce an additive reduction in myocardial contractility because of negative chronotropic and inotropic effects. CYP2D6 Inhibitors: Potent inhibitors of the CYP2D6 enzyme may [0m
[31mincrease the plasma concentration of metoprolol which would mimic the pharmacokinetics of CYP2D6 poor metabolizer [0m[1;31m([0m[31msee Pharmacokinetics section[0m[1;31m)[0m[31m. Increase in plasma concentrations of metoprolol would [0m
[31mdecrease the cardioselectivity of metoprolol. METOPROLOL TARTRATE: drug_interactions: Known clinically significant potent inhibitors of CYP2D6 are antidepressants such as fluvoxamine, fluoxetine, [0m
[31mparoxetine, sertraline, bupropion, clomipramine, and desipramine; antipsychotics such as chlorpromazine, fluphenazine, haloperidol, and thioridazine; antiarrhythmics such as quinidine or propafenone; [0m
[31mantiretrovirals such as ritonavir; antihistamines such as diphenhydramine; antimalarials such as hydroxychloroquine or quinidine; antifungals such as terbinafine. Hydralazine: Concomitant [0m
[31madministration of hydralazine may inhibit presystemic metabolism of metoprolol leading to increased concentrations of metoprolol. METOPROLOL TARTRATE: drug_interactions: Alpha-adrenergic Agents: [0m
[31mAntihypertensive effect of alpha-adrenergic blockers such as guanethidine, betanidine, reserpine, alpha-methyldopa or clonidine may be potentiated by beta-blockers including metoprolol. [0m
[31mBeta-adrenergic blockers may also potentiate the postural hypotensive effect of the first dose of prazosin, probably by preventing reflex tachycardia. On the contrary, beta adrenergic blockers may [0m
[31malso potentiate the hypertensive response to withdrawal of clonidine in patients receiving concomitant clonidine and beta-adrenergic blocker. If a patient is treated with clonidine and metoprolol [0m
[31mconcurrently, and clonidine treatment is to be discontinued, stop metoprolol several days before clonidine is withdrawn. Rebound hypertension that can follow withdrawal of clonidine may be increased [0m
[31min patients receiving concurrent beta-blocker treatment.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: METOPROLOL TARTRATE has been shown to reduce the risk of myocardial infarction. In a large, double-blind, placebo-controlled clinical study, metoprolol was shown to reduce [0m[1;32m3[0m[32m-month mortality by[0m
[1;32m36[0m[32m% in patients with suspected or definite myocardial infarction. The study included patients who were treated as soon as possible after their arrival in the hospital, once their clinical condition [0m
[32mhad stabilized. The treatment consisted of both intravenous and oral administration of metoprolol or placebo, and the beneficial effects were observed with metoprolol treatment.[0m

[32mSOURCE: METOPROLOL TARTRATE label[0m
[32mEXTRACT_START_END: In a large [0m[1;32m([0m[1;32m1[0m[32m,[0m[1;32m395[0m[32m patients randomized[0m[1;32m)[0m[32m...[0m[32mindependent of the interval between onset of symptoms and initiation of therapy.[0m
*[1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: METOPROLOL TARTRATE has been shown to reduce the[0m
[34mrisk of myocardial infarction. In a large, double-blind, placebo-controlled clinical study, metoprolol was shown to reduce [0m[1;34m3[0m[34m-month mortality by [0m[1;34m36[0m[34m% in patients with suspected or definite myocardial [0m
[34minfarction. The study included patients who were treated as soon as possible after their arrival in the hospital, once their clinical condition had stabilized. The treatment consisted of both [0m
[34mintravenous and oral administration of metoprolol or placebo, and the beneficial effects were observed with metoprolol treatment.[0m

[34mSOURCE: METOPROLOL TARTRATE label[0m
[34mEXTRACT_START_END: In a large [0m[1;34m([0m[1;34m1[0m[34m,[0m[1;34m395[0m[34m patients randomized[0m[1;34m)[0m[34m...[0m[34mindependent of the interval between onset of symptoms and initiation of therapy.[0m
 [1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether METOPROLOL TARTRATE increases or decreases the risk of myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that METOPROLOL TARTRATE has been shown to reduce the risk of myocardial infarction. In a large, double-blind, placebo-controlled clinical study, metoprolol reduced 3-month[0m
[32mmortality by 36% in patients with suspected or definite myocardial infarction when treated as soon as possible after their arrival in the hospital."[0m[32m,[0m
[32m      [0m[32m"The beneficial effects of METOPROLOL TARTRATE were observed with both intravenous and oral administration in the study mentioned in the METOPROLOL TARTRATE label."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"METOPROLOL TARTRATE decreases the risk of myocardial infarction."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does METOPROLOL TARTRATE increase or decrease the risk of myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether METOPROLOL TARTRATE increases or decreases the risk of myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that METOPROLOL TARTRATE has been shown to reduce the risk of myocardial infarction. In a large, double-blind, placebo-controlled clinical study, metoprolol reduced 3-month[0m
[34mmortality by 36% in patients with suspected or definite myocardial infarction when treated as soon as possible after their arrival in the hospital."[0m[34m,[0m
[34m      [0m[34m"The beneficial effects of METOPROLOL TARTRATE were observed with both intravenous and oral administration in the study mentioned in the METOPROLOL TARTRATE label."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"METOPROLOL TARTRATE decreases the risk of myocardial infarction."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does METOPROLOL TARTRATE increase or decrease the risk of myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether METOPROLOL TARTRATE increases or decreases the risk of myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded that METOPROLOL TARTRATE has been shown to reduce the risk of myocardial infarction. In a large, double-blind, placebo-controlled clinical study, metoprolol reduced [0m[1;31m3[0m[31m-month [0m
[31mmortality by [0m[1;31m36[0m[31m% in patients with suspected or definite myocardial infarction when treated as soon as possible after their arrival in the hospital.[0m
[1;31m3[0m[31m. The beneficial effects of METOPROLOL TARTRATE were observed with both intravenous and oral administration in the study mentioned in the METOPROLOL TARTRATE label.[0m
[31m        -----[0m
[31m        Final answer: METOPROLOL TARTRATE decreases the risk of myocardial infarction.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mMETOPROLOL TARTRATE decreases the risk of myocardial infarction. This conclusion is based on a large, double-blind, placebo-controlled clinical study mentioned in the METOPROLOL TARTRATE label, which [0m
[32mshowed that metoprolol reduced [0m[1;32m3[0m[32m-month mortality by [0m[1;32m36[0m[32m% in patients with suspected or definite myocardial infarction when treated as soon as possible after their arrival in the hospital. The [0m
[32mbeneficial effects were observed with both intravenous and oral administration of metoprolol.[0m
